Tutorials
Cellectar Biosciences Inc logo

Cellectar Biosciences Inc

$ 5.18 +0.175 (+3.5%) 10:08 PM EST
P/E:
At Loss
P/B:
1.22
Market Cap:
$ 31.62M
Enterprise V:
$ 2.64M
Volume:
19.80K
Avg Vol (2M):
24.22K
Also Trade In:
Volume:
19.80K
Market Cap $:
31.62M
PE Ratio:
At Loss
Avg Vol (2-Month):
24.22K
Enterprise Value $:
2.64M
PB Ratio:
1.22
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website SEC Filings Stock Report
Dataset
Financial Download Tutorials

Business Description

Cellectar Biosciences Inc
NAICS : 325412 SIC : 2834
100 Campus Drive, Florham Park, NJ, USA, 07932
Description
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and better safety as a result of fewer off-target effects. Its lead PDC therapeutic, iopofosine is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells.
Name Current Vs Industry Vs History
Cash-To-Debt 113.46
Equity-to-Asset 0.85
Debt-to-Equity 0.01
Debt-to-EBITDA -0.01
Interest Coverage N/A
N/A
N/A
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 0
Distress
Grey
Safe
Beneish M-Score -3.29
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 72.8
9-Day RSI 62.42
14-Day RSI 58.75
6-1 Month Momentum % -26.34
12-1 Month Momentum % -58.81

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 6.75
Quick Ratio 6.75
Cash Ratio 6.59

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -134.6
Name Current Vs Industry Vs History
ROE % -62.06
ROA % -55.87
ROIC % -2831.16
ROC (Joel Greenblatt) % -4501.51
ROCE % -61.76

Financials (Next Earnings Date:2022-08-09 Est.)

CLRB's 30-Y Financials

Guru Trades

See Details
To
EMBED
SAVE

Insider Trades

See Details
To
EMBED
SAVE

Gurus Latest Trades with NAS:CLRB

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
EMBED
SAVE
Dividend
To
EMBED
SAVE

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

EMBED

Valuation Box

Year:
EMBED

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 0
EPS (TTM) ($) -4
Beta 1.58
Volatility % 52.61
14-Day RSI 58.75
14-Day ATR ($) 0.523966
20-Day SMA ($) 4.590675
12-1 Month Momentum % -58.81
52-Week Range ($) 3.37 - 10.9
Shares Outstanding (Mil) 6.11

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Cellectar Biosciences Inc Filings

Document Form Filing Date
No Filing Data

Headlines

See More